Botulinum Toxin Type A in the Treatment of Raynaud's Phenomenon

Neumeister, Michael W.

doi:10.1016/j.jhsa.2010.09.019

Cited by 127 publications

(165 citation statements)

References 20 publications

Supporting

Mentioning

142

Contrasting

Unclassified

Order By: Relevance

“…39 -40 The ability of BoNTA to inhibit sympathetic nervous input reduces vasoconstriction, which is the most likely mechanism for improvement seen in Raynaud phenomenon patients following BoNTA injection. [7][8][9][10] The increased blood flow accompanying BoNTA administration might also be considered for other vaso-occlusive disorders and might serve as an adjunct therapy to promote healing.…”

Section: Discussionmentioning

confidence: 99%

“…[1][2][3][4][5][6] In addition, botulinum toxin is emerging as a treatment modality for Raynaud phenomenon. [7][8][9][10] The mechanism of action of BoNTA at the neuromuscular junction and the functional recovery of the nerve and muscle are well established [11][12][13][14][15][16][17][18] ; however, little information is available regarding toxin effects on the local vasculature. [7][8][9]19 Arteriolar diameter and blood flow is predominantly controlled by the sympathetic nervous system, which releases norepinephrine after stimulation and results in ␣-adrenergic receptor-mediated vasoconstriction.…”

mentioning

confidence: 99%

See 1 more Smart Citation

The Effect of Botulinum Neurotoxin-A on Blood Flow in Rats: A Potential Mechanism for Treatment of Raynaud Phenomenon

Stone

Koman

Callahan

et al. 2012

The Journal of Hand Surgery

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

The Effect of Botulinum Neurotoxin-A on Blood Flow in Rats: A Potential Mechanism for Treatment of Raynaud Phenomenon

Stone

Koman

Callahan

et al. 2012

The Journal of Hand Surgery

View full text Add to dashboard Cite

“…All studies, summarized in Table 6 , enrolled only a few patients and are totally lacking a standardization injection protocol and outcomes. Therefore, some authors did not declare well the coexistence of an SSc or other diseases with the RP, creating a bias in the evaluation of BoNT-A efficacy [98][99][100][101] . Table 7 illustrates the aspects of these studies.…”

Section: Raynaud Phenomenonmentioning

confidence: 99%

Botulinum Toxin Off-Label Use in Dermatology: A Review

Campanati

Martina

Giuliodori

et al. 2017

Skin Appendage Disord

View full text Add to dashboard Cite

focal hyperhidrosis, aesthetic medicine and neurological conditions with a strong efficacy and safety profile [1][2][3][4][5][6][7] . The enormous therapeutic potential of this drug contributed to a number of broad applications, especially in dermatological diseases. A large number of these indications are still lacking shared, approved protocols for dilution, doses, and timing of follow-up and retreatment. Also the injection techniques are still debated, depending on the operator's experience, angle of injection and depth. We have previously published a novel injection approach consisting in a needle adaptor that ensures a uniform administration of the toxin [3] . The aim of this review was to collect and analyze the published data concerning the most relevant off-label indications of BoNT-A. MethodsA PubMed search from 1950 to July 2016 was performed to identify any reports on the use of botulinum toxin in off-label indications concerning dermatology. We detected these articles using the terms "botulinum toxin dermatology," "botulinum toxin treatment," "botulinum toxin off-label," and meshed with a secondary search of studies pertaining to each indication. Only studies in English were reviewed. All studies that met the criteria were included and summarized in this review. KeywordsBotulinum toxin · Off-label therapy · Keloids · Hidradenitis suppurativa · Folds dermatitis Abstract Background: Botulinum toxin is a neurotoxin produced by the bacterium Clostridium botulinum which causes a flaccid muscle paralysis. It is currently used for aesthetic treatments and in the focal hyperhidrosis. Recently, botulinum toxin has also been used experimentally in many other dermatological conditions with good results. Objective: To review and analyze the possible botulinum toxin off-label applications published. Methods: A retrospective review of the published data was conducted. Conclusions: this potent drug can lead to several off-label indications of interest for dermatologists. Further clinical trials are still needed to better understand the real efficacy and safety of these applications and to standardize injection and dose protocols.

show abstract

“…of patients Results Serri et al (2013) 18 pts with systemic sclerosis Thirty days after injection, complete healing of ulcers occurred and the symptomatology significantly improved Neumeister (2010) A total of 33 pts (14 men and 19 women)…”

Section: Studymentioning

confidence: 99%

“…Most of these studies are case series (Liu, 2006;Heckmann et al, 2002;Kossintseva et al, 2011;Iorio et al, 2012;Serri et al, 2013) , one is randomized controlled trial (Neumeister, 2010) and two case reports (Neumeister et al, 2009;Fregene et al, 2009) (Table 3). In all of these studies the patients were presented with chronic ischemic hand pain, ulceration and loss of function.…”

Section: Raynaud Syndromementioning

confidence: 99%

Botulinum toxin: Non cosmetic and off-label dermatological uses

Alghamdi

Alghanemy

Joharji

et al. 2015

Journal of Dermatology & Dermatologic Surgery

View full text Add to dashboard Cite

Botulinum toxin (BT-A) is a neurotoxin which is produced by the Gram-positive anaerobic bacterium Clostridium botulinum. The efficacy of Botulinum toxin in treating hyperhidrosis and the glabellar lines is well known and FDA approved.Because BT-A inhibits the release of acetylcholine and many other neurotransmitters such as norepinephrine and substance P at the level of nerve ending, this toxin has been used to treat a lot of dermatological disorders which are thought to be triggered by these neurotransmitters.In this article we are discussing the medical off-label uses of BT-A in dermatology.ª 2014 Production and hosting by Elsevier B.V. on behalf of King Saud University.

show abstract

Botulinum Toxin Type A in the Treatment of Raynaud's Phenomenon

Cited by 127 publications

References 20 publications

The Effect of Botulinum Neurotoxin-A on Blood Flow in Rats: A Potential Mechanism for Treatment of Raynaud Phenomenon

The Effect of Botulinum Neurotoxin-A on Blood Flow in Rats: A Potential Mechanism for Treatment of Raynaud Phenomenon

Botulinum Toxin Off-Label Use in Dermatology: A Review

Botulinum toxin: Non cosmetic and off-label dermatological uses

Contact Info

Product

Resources

About